Drug Trial Radar · NCT04322539
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
691
Actual
Start
Aug 12, 2020
Primary completion
Jul 29, 2022
Study completion Apr 24, 2024
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.
Conditions
- Metastatic Colorectal Cancer
- Metastatic Colon Cancer
Interventions
FruquintinibDrug
Oral VEGFR inhibitor
PlaceboDrug
Placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization to death from any cause (up to 22 months)
Locations
153 sites in 14 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Arizona Oncology Associates, PC-HOPE
Tucson, Arizona
California Research Institute (CRI)
Los Angeles, California
City of Hope Comprehensive Cancer Center
Los Angeles, California
Rocky Mountain Cancer Center
Aurora, Colorado
The George Washington University Medical Center
Washington D.C., District of Columbia
Sarah Cannon Research Institute-S-Ft. Myers (FCS South)
Fort Myers, Florida
Mayo Clinic Florida
Jacksonville, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida
Sarah Cannon Research Institute-N-St Pete (FCS North)
St. Petersburg, Florida
Sarah Cannon Research Institute-Pan-Tallahassee (FCS Panhandle)
Tallahassee, Florida
Sarah Cannon Research-E-WPB (Florida Cancer Specialists-FCS East)
West Palm Beach, Florida
Emory Winship Cancer Institute
Atlanta, Georgia
Illinois Cancer Specialists
Arlington Heights, Illinois
University of Chicago Medical Center
Chicago, Illinois
Affiliated Oncologists
Chicago Ridge, Illinois
XCancer / Central Care Cancer Center
Garden City, Kansas
University of Louisville - James Brown Cancer Center
Louisville, Kentucky
Norton Cancer Institute Audubon
Louisville, Kentucky
Hematology Oncology Clinic
Baton Rouge, Louisiana
XCancer / Pontchartrain Cancer Center
Hammond, Louisiana
Maryland Oncology Hematology, P.A.
Columbia, Maryland
University of Michigan Health System
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Minnesota Oncology
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
Center for Pharmaceutical Research
Kansas City, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
XCancer / New Mexico Oncology & Hematology Consultants
Albuquerque, New Mexico
Charleston Oncology
Charleston, South Carolina
Sarah Cannon Tennessee Oncology
Nashville, Tennessee
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Texas Oncology - Austin
Austin, Texas
Texas Oncology Baylor Sammons
Dallas, Texas
Texas Oncology-El Paso
El Paso, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology-McAllen
McAllen, Texas
Texas Oncology-San Antonio
San Antonio, Texas
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.